Mark Reimer is an experienced leader in the development of new drug therapies with over twenty-five years of progressive scientific, managerial and executive responsibilities in the field of drug research, including ADME/T and bioanalysis. He obtained his PhD (Chemistry) from the University of Manitoba and subsequently undertook post-doctoral research in pharmaceutical sciences (University of Arizona) and biomarker analysis (McGill University). Mark led pre-clinical research efforts at Theratechnologies, a major Canadian biopharmaceutical company, and was responsible for the inception, build-out, and consistent profitability of the non-clinical drug metabolism and bioanalysis unit at MDS Pharma Services, at the time one of the world’s top-five contract research organizations. In his current role, Mark is responsible for the day-to-day performance of the Certara Strategic Consulting (CSC) Canadian operation (25 staff) and is a participating member of the global CSC Management Team which oversees the organization, staffing, contracting, business development, client management, and profitability of CSC.
Executive Director, Integrated Drug Development